Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARQT Arcutis Biotherapeutics	$14.52 +1.3%	$14.04	$7.86 ▼ $17.75	$1.73B	1.77	2.14 million shs	247,466 shs
BBIO BridgeBio Pharma	$46.27 +0.8%	$39.79	$21.72 ▼ $48.68	$8.79B	1.15	2.55 million shs	434,078 shs
LNTH Lantheus	$71.65 +0.1%	$78.80	$69.12 ▼ $118.21	$4.95B	0.12	981,108 shs	285,364 shs
ROIV Roivant Sciences	$11.58 +0.8%	$11.17	$8.73 ▼ $13.06	$7.87B	1.15	5.72 million shs	782,159 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARQT Arcutis Biotherapeutics	-2.25%	-9.81%	+3.76%	+3.69%	+47.08%
BBIO BridgeBio Pharma	-1.31%	-3.75%	+9.99%	+34.29%	+75.26%
LNTH Lantheus	+1.97%	-13.85%	-9.64%	-28.13%	-38.73%
ROIV Roivant Sciences	+0.35%	-1.29%	+0.26%	+10.17%	+4.36%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARQT Arcutis Biotherapeutics	2.2113 of 5 stars	3.4	1.0	0.0	2.9	1.7	0.6
BBIO BridgeBio Pharma	4.5811 of 5 stars	4.5	1.0	3.9	2.9	3.3	0.6
LNTH Lantheus	4.6703 of 5 stars	3.4	2.0	4.2	3.9	2.5	1.9
ROIV Roivant Sciences	2.7906 of 5 stars	3.6	3.0	0.0	2.6	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARQT Arcutis Biotherapeutics	2.83	Moderate Buy	$18.80	29.48% Upside
BBIO BridgeBio Pharma	3.00	Buy	$61.50	32.92% Upside
LNTH Lantheus	2.83	Moderate Buy	$131.20	83.11% Upside
ROIV Roivant Sciences	3.25	Buy	$16.50	42.55% Upside

Current Analyst Ratings Breakdown

Latest ARQT, ROIV, LNTH, and BBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/21/2025	BBIO BridgeBio Pharma	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$66.00
7/16/2025	LNTH Lantheus	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
7/14/2025	BBIO BridgeBio Pharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$63.00 ➝ $68.00
7/14/2025	BBIO BridgeBio Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$70.00
7/11/2025	BBIO BridgeBio Pharma	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$58.00 ➝ $67.00
7/10/2025	ROIV Roivant Sciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$19.00
7/9/2025	BBIO BridgeBio Pharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$60.00
6/30/2025	BBIO BridgeBio Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$67.00 ➝ $76.00
6/25/2025	BBIO BridgeBio Pharma	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $54.00
6/23/2025	LNTH Lantheus	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$122.00 ➝ $109.00
6/18/2025	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00

(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARQT Arcutis Biotherapeutics	$196.54M	8.81	N/A	N/A	$1.35 per share	10.76
BBIO BridgeBio Pharma	$221.90M	39.59	N/A	N/A	($7.71) per share	-6.00
LNTH Lantheus	$1.53B	3.23	$7.24 per share	9.89	$15.65 per share	4.58
ROIV Roivant Sciences	$29.05M	270.87	N/A	N/A	$7.45 per share	1.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARQT Arcutis Biotherapeutics	-$140.04M	-$1.04	N/A	N/A	N/A	-60.95%	-80.66%	-32.94%	8/13/2025 (Estimated)
BBIO BridgeBio Pharma	-$535.76M	-$3.53	N/A	N/A	N/A	-524.25%	N/A	-94.43%	7/30/2025 (Estimated)
LNTH Lantheus	$312.44M	$3.52	20.32	11.35	N/A	16.55%	36.99%	20.55%	7/30/2025 (Estimated)
ROIV Roivant Sciences	-$171.98M	-$0.25	N/A	N/A	N/A	-225.71%	-14.76%	-13.69%	8/6/2025 (Estimated)

Latest ARQT, ROIV, LNTH, and BBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q1 2026	ROIV Roivant Sciences	-$0.23	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	ARQT Arcutis Biotherapeutics	-$0.19	N/A	N/A	N/A	$72.70 million	N/A
8/7/2025	Q2 2025	BBIO BridgeBio Pharma	-$0.50	N/A	N/A	N/A	N/A	N/A
7/30/2025	Q2 2025	LNTH Lantheus	$1.65	N/A	N/A	N/A	$389.69 million	N/A
5/29/2025	Q4 2025	ROIV Roivant Sciences	-$0.16	-$0.31	-$0.15	-$0.29	$62.17 million	$7.57 million
5/7/2025	Q1 2025	LNTH Lantheus	$1.64	$1.53	-$0.11	$1.02	$377.37 million	$372.76 million
5/6/2025	Q1 2025	ARQT Arcutis Biotherapeutics	-$0.21	-$0.20	+$0.01	-$0.20	$64.80 million	$65.85 million
4/29/2025	Q1 2025	BBIO BridgeBio Pharma	-$1.00	-$0.88	+$0.12	-$0.88	$57.14 million	$36.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARQT Arcutis Biotherapeutics	N/A	N/A	N/A	N/A	N/A
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARQT Arcutis Biotherapeutics	0.75	3.55	3.37
BBIO BridgeBio Pharma	N/A	4.57	4.54
LNTH Lantheus	0.49	5.74	5.46
ROIV Roivant Sciences	N/A	33.47	33.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARQT Arcutis Biotherapeutics	N/A
BBIO BridgeBio Pharma	99.85%
LNTH Lantheus	99.06%
ROIV Roivant Sciences	64.76%

Insider Ownership

Company	Insider Ownership
ARQT Arcutis Biotherapeutics	9.40%
BBIO BridgeBio Pharma	18.20%
LNTH Lantheus	2.00%
ROIV Roivant Sciences	7.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARQT Arcutis Biotherapeutics	150	119.20 million	108.00 million	Optionable
BBIO BridgeBio Pharma	400	189.88 million	155.32 million	Optionable
LNTH Lantheus	700	69.19 million	67.80 million	Optionable
ROIV Roivant Sciences	860	679.81 million	626.10 million	Optionable

ARQT, ROIV, LNTH, and BBIO Headlines

Recent News About These Companies

Mutual of America Capital Management LLC Sells 142,139 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

July 20 at 3:51 AM | marketbeat.com

CenterBook Partners LP Buys New Stake in Roivant Sciences Ltd. (NASDAQ:ROIV)

July 16, 2025 | marketbeat.com

Bank of New York Mellon Corp Has $40.36 Million Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

July 15, 2025 | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Stock Rating Upgraded by The Goldman Sachs Group

July 13, 2025 | americanbankingnews.com

Roivant Sciences Ltd. (ROIV) - Yahoo Finance

July 10, 2025 | finance.yahoo.com

Roivant Sciences (NASDAQ:ROIV) Earns Buy Rating from Analysts at The Goldman Sachs Group

July 10, 2025 | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Sees Unusually-High Trading Volume - Still a Buy?

July 9, 2025 | marketbeat.com

DAVENPORT & Co LLC Reduces Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

July 9, 2025 | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Stock Position Decreased by New York State Teachers Retirement System

July 9, 2025 | marketbeat.com

'Just the beginning': Vivek Ramaswamy breaks record in raising fund for Guv election campaign, $8.5 million in five months

June 28, 2025 | msn.com

Roivant Sciences’ president Venker sells $1.15 million in shares

June 26, 2025 | investing.com

Investors Buy Large Volume of Roivant Sciences Call Options (NASDAQ:ROIV)

June 26, 2025 | marketbeat.com

Penn Davis Mcfarland Inc. Has $17.23 Million Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

June 25, 2025 | marketbeat.com

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $1,145,000.00 in Stock

June 25, 2025 | insidertrades.com

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker Sells 100,000 Shares

June 24, 2025 | marketbeat.com

Roivant Sciences Subsidiary Pulmovant Publishes Positive Phase 1 Data for Inhaled PH Treatment Mosliciguat

June 24, 2025 | msn.com

Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Sells 565,266 Shares of Stock

June 24, 2025 | insidertrades.com

Roivant Sciences (ROIV) : Ramaswamy vend des actions pour 13 millions

June 23, 2025 | fr.investing.com

Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Sells $6,472,295.70 in Stock

June 23, 2025 | marketbeat.com

Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Sells 577,007 Shares of Stock

June 23, 2025 | marketbeat.com

Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics

June 16, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARQT, ROIV, LNTH, and BBIO Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

$14.52 +0.18 (+1.26%)

As of 11:38 AM Eastern

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

BridgeBio Pharma NASDAQ:BBIO

$46.27 +0.37 (+0.81%)

As of 11:38 AM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Lantheus NASDAQ:LNTH

$71.65 +0.09 (+0.13%)

As of 11:38 AM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Roivant Sciences NASDAQ:ROIV

$11.58 +0.10 (+0.83%)

As of 11:38 AM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time